Arcutis Biotherapeutics, Inc. (ARQT) NASDAQ
21.46
+0.02(+0.09%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
21.46
+0.02(+0.09%)
Currency In USD
Address
3027 Townsgate Road
Westlake Village, CA 91361
United States of America (the)
Phone
805 418 5006
Website
Sector
Healthcare
Industry
Biotechnology
Employees
342
First IPO Date
January 31, 2020
| Name | Title | Pay | Year Born |
| Todd Franklin Watanabe | President, Chief Executive Officer & Director | 1.31M | 1968 |
| Bhaskar Chaudhuri | Co-Founder & Director Emeritus | 60,054 | 1955 |
| Bethany Dudek | Chief Technical Officer | 584,551 | N/A |
| Latha Vairavan | Senior Vice President & Chief Financial Officer | 644,904 | 1978 |
| Masaru Matsuda | Executive VP, Chief Legal Officer & Corporate Secretary | 787,699 | 1971 |
| Patrick E. Burnett | Executive Vice President & Chief Medical Officer | 883,376 | 1972 |
| L. Todd Edwards | Executive Vice President & Chief Commercial Officer | 897,205 | 1964 |
| Aleen Hosdaghian | Vice President of Marketing | 0 | N/A |
| Douglas DiRuggiero DMSC | Advanced Practitioner | 0 | N/A |
| Jeff Kiekhofer | VP & Controller | 0 | N/A |
| Rajvir Madan | Chief Digital & Technology Officer | 0 | N/A |
| Steve Arias | Vice President of Compliance & Privacy | 0 | N/A |
| Amanda Sheldon | Head of Corporate Communications | 0 | N/A |
| Brian Schoelkopf | Head of Investor Relations | 0 | N/A |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.